ReviewFrontiers in psychiatry2025
Effects of cognitive behavioral therapy on cognition, neuropsychiatric symptoms, and quality of life in Alzheimer's disease: a meta-analysis.
Review in Frontiers in psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Stress, stress systems, and Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder, often accompanied by cognitive decline and neuropsychiatric symptoms, which substantially impair patients' quality of life. Cognitive behavioral therapy (CBT) has shown effects in improving mood and quality of life in depression and anxiety, but systematic evidence of its application in AD is still limited. Objective: This study aims to systematically assess the efficacy of CBT interventions on global cognition, neuropsychiatric symptoms (including depression severity) and Quality of Life (QoL) in AD. Method: PubMed, Embase, Cochrane, and Web of Science databases were researched from the inception of each database to March 2025. The search strategy included MESH terms "Alzheimer Disease" and "Cognitive Behavioral Therapy", combined with the Boolean operator "AND". Randomized controlled trials involving CBT-adapted protocols were included. Data were pooled using random-effects models (Hedges' g with 95%CIs), with subgroup analyses by intervention duration. Meta-analyses were performed using Stata MP 18.0, with bias risk assessed by the Cochrane Risk of Bias tool RevMan 5.4. Result: A total of 15 randomized controlled trials (n=2,135 participants) were included. The meta-analysis showed that CBT significantly improved global cognition (MMSE: SMD = 0.67, 95%CI=0.31 to 1.02, p<0.001), though heterogeneity was high (I²=86.9%). No significant effects were observed for neuropsychiatric symptoms, or QoL. Subgroup analyses revealed medium-term interventions (8-16 weeks) reduced depressive symptoms and improved QoL, while long-term CBT (>16 weeks) enhanced cognition. Conclusions: CBT demonstrates significant benefits for global cognition in AD, with medium-term interventions effective for mood and QoL outcomes. These findings support CBT intervention as viable non-pharmacological strategies for AD management, though methodological limitations and considerable heterogeneity warrant cautious interpretation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.